{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:32:37Z","timestamp":1790188357058,"version":"4.1.0"},"reference-count":84,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Subst\ufffdAbuse"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Concerns about the misuse of over the counter (OTC) and prescription only medication (POM) are due to their impact upon physical\/mental wellbeing, drug interactions and drug-related deaths. Improving an understanding of the pattern of use by people accessing specialist substance misuse services (SMSs) should enable improvements to treatment provision.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>To review the literature on the misuse of OTC\/POM among adults accessing SMS, including the pattern of use, types of medication and associated characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This review is reported in line with PRISMA. The protocol has been registered on PROSPERO (CRD42020135216) and separately published. A search of Cochrane, OVID Medline, Pubmed, Scopus and Web of Science databases and grey literature was undertaken. Only English language publications outlining OTC\/POM misuse by adults in receipt of psychological\/pharmacological interventions for substance misuse were included. Two reviewers conducted the title, abstract and full-text reviews using predetermined selection criteria and a piloted data extraction form to ensure a consistent approach. A third reviewer resolved disagreements and the Mixed Methods Appraisal Tool assessed for bias. Ethical approval was not required.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Thirteen studies with notable heterogeneity were included in the narrative synthesis after non-UK-based and ineligible publications were excluded, from the 143 potentially relevant papers. To reduce bias all studies were included in the analysis and GRADE-CERQual was applied. \u2018High confidence\u2019 was identified for all review findings, despite moderate methodological limitations. Antihistamine, benzodiazepine and opioid misuse was mentioned most frequently. Usage patterns and supply sources varied. Adverse consequences and polypharmacy are concerning. Withdrawal symptoms perpetuated misuse, often alongside illicit substance use, comorbid psychiatric\/pain disorders and street drug shortages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>OTC\/POM misuse is common amongst adults accessing SMS. A renewed approach to withdrawal management is required. The limited number of studies may impact on generalisability but allowed for a more detailed review. Restricting to UK studies improved relevance due to drug market variations and availability of medicines in different countries. Further UK-based research on OTC\/POM misuse in SMS is needed to build upon the current paucity in the published literature.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/11782218221111833","type":"journal-article","created":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T02:58:05Z","timestamp":1657594685000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Misuse of Over the Counter and Prescription Only Medication by Adults Accessing Specialist Treatment Services in the UK: A Narrative Synthesis"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0893-7936","authenticated-orcid":false,"given":"Rosalind","family":"Gittins","sequence":"first","affiliation":[{"name":"Clinical Department, Humankind, Durham, UK"},{"name":"Aston Pharmacy School, Aston University, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Missen","sequence":"additional","affiliation":[{"name":"Gilead Sciences, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Maidment","sequence":"additional","affiliation":[{"name":"Aston Pharmacy School, Aston University, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,7,11]]},"reference":[{"key":"bibr1-11782218221111833","doi-asserted-by":"publisher","DOI":"10.2174\/1874473710801030255"},{"key":"bibr2-11782218221111833","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2013.05.053"},{"key":"bibr3-11782218221111833","unstructured":"United Nations Office on Drugs and Crime. The non-medical use of prescription drugs: policy direction issues. 2011. Accessed January 12, 2022. https:\/\/www.unodc.org\/documents\/drug-prevention-and-treatment\/nonmedical-use-prescription-drugs.pdf"},{"key":"bibr4-11782218221111833","unstructured":"Scottish Drug Forum. Moving beyond people first language. 2020. Accessed November 24, 2021. https:\/\/www.sdf.org.uk\/wp-content\/uploads\/2020\/10\/Moving-Beyond-People-First-Language.pdf"},{"key":"bibr5-11782218221111833","volume":"20","author":"Roberts AW","year":"2014","journal-title":"J Manag Care Spec Pharm"},{"key":"bibr6-11782218221111833","doi-asserted-by":"publisher","DOI":"10.12968\/hosp.1999.60.3.1745"},{"key":"bibr7-11782218221111833","unstructured":"DrugWatch. Information Sheet Lean (Purple Drank\/Syrup) Version 1.0 (Professionals). 2018. Accessed November 24, 2021. http:\/\/thedrugswheel.com\/drugwatch\/Lean_Infosheet_DrugWatch_1_0_Pro.pdf"},{"key":"bibr8-11782218221111833","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2007.02096.x"},{"key":"bibr9-11782218221111833","doi-asserted-by":"publisher","DOI":"10.1197\/j.aem.2005.12.011"},{"key":"bibr10-11782218221111833","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2012.07.004"},{"key":"bibr11-11782218221111833","doi-asserted-by":"publisher","DOI":"10.1111\/add.13843"},{"key":"bibr12-11782218221111833","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002965"},{"key":"bibr13-11782218221111833","unstructured":"Office for National Statistics. Deaths related to drug poisoning in England and Wales: 2020 registrations. 2021. Accessed January 12, 2022. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/deaths\/bulletins\/deathsrelatedtodrugpoisoninginenglandandwales\/2020"},{"key":"bibr14-11782218221111833","unstructured":"National Records of Scotland. Drug-related deaths rise. 2021. Accessed January 12, 2022. https:\/\/www.nrscotland.gov.uk\/news\/2021\/drug-related-deaths-rise"},{"key":"bibr15-11782218221111833","doi-asserted-by":"publisher","DOI":"10.1177\/0269881120959615"},{"key":"bibr16-11782218221111833","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.161421"},{"key":"bibr17-11782218221111833","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.657397"},{"key":"bibr18-11782218221111833","first-page":"1","volume":"28","author":"Ilgen M","year":"2011","journal-title":"Psychiatric Times"},{"key":"bibr19-11782218221111833","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2007.02.012"},{"key":"bibr20-11782218221111833","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000436"},{"key":"bibr21-11782218221111833","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-017-2387-z"},{"key":"bibr22-11782218221111833","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-014-0544-y"},{"key":"bibr23-11782218221111833","doi-asserted-by":"publisher","DOI":"10.1002\/pnp.550"},{"key":"bibr24-11782218221111833","doi-asserted-by":"publisher","DOI":"10.1177\/20503245211021193"},{"key":"bibr25-11782218221111833","unstructured":"Advisory Council on the Misuse of Drugs. Diversion and Illicit Supply of Medicines. 2016. Accessed November 24, 2021. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/580296\/Meds_report-_final_report_15_December_LU__2_.pdf"},{"key":"bibr26-11782218221111833","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-002913"},{"key":"bibr27-11782218221111833","first-page":"722","volume":"38","author":"Fingleton NA","year":"2016","journal-title":"J Public Health"},{"key":"bibr28-11782218221111833","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2009.00603.x"},{"key":"bibr29-11782218221111833","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcx076"},{"key":"bibr30-11782218221111833","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1055\/s-2008-1078724","volume":"70","author":"K\u00fcfner H","year":"2008","journal-title":"Gesundheitswesen"},{"key":"bibr31-11782218221111833","doi-asserted-by":"publisher","DOI":"10.2196\/12354"},{"key":"bibr32-11782218221111833","first-page":"309","volume":"108","author":"McNamara S","year":"2015","journal-title":"Ir Med J"},{"key":"bibr33-11782218221111833","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2015.02.004"},{"key":"bibr34-11782218221111833","doi-asserted-by":"publisher","DOI":"10.2165\/11316590-000000000-00000"},{"key":"bibr35-11782218221111833","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2014.12.010"},{"key":"bibr36-11782218221111833","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00046"},{"key":"bibr37-11782218221111833","doi-asserted-by":"publisher","DOI":"10.1177\/1049732315613764"},{"key":"bibr38-11782218221111833","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/pubmed\/fdv150","volume":"38","author":"Wright J","year":"2016","journal-title":"J Public Health"},{"key":"bibr39-11782218221111833","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(19)30331-1"},{"key":"bibr40-11782218221111833","unstructured":"Public Health England. Dependence and withdrawal associated with some prescribed medicines: an evidence review. 2019. Accessed November 24, 2021. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/940255\/PHE_PMR_report_Dec2020.pdf"},{"key":"bibr41-11782218221111833","volume":"6","author":"Butler SF","year":"2010","journal-title":"J Opioid Manag"},{"key":"bibr42-11782218221111833","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph15091978"},{"key":"bibr43-11782218221111833","unstructured":"Carey J, Boyle KL, Rhyee S. Gender differences in prescription medication abuse. 2014. Paper presented at: Society for Academic Emergency Medicine 2014 Annual Meeting - Dallas. Accessed November 24, 2021. https:\/\/www.acmt.net\/_Library\/ToxIC\/FINALsaemabstract_for_ToxIC.pdf"},{"key":"bibr44-11782218221111833","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-017-2538-z"},{"key":"bibr45-11782218221111833","doi-asserted-by":"publisher","DOI":"10.1037\/adb0000579"},{"key":"bibr46-11782218221111833","doi-asserted-by":"publisher","DOI":"10.3109\/10826084.2014.880723"},{"key":"bibr47-11782218221111833","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2009.05.017"},{"key":"bibr48-11782218221111833","doi-asserted-by":"publisher","DOI":"10.3109\/10826084.2013.800112"},{"key":"bibr49-11782218221111833","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(99)00137-2"},{"key":"bibr50-11782218221111833","unstructured":"Public Health England. Substance misuse treatment for adults: statistics 2019 to 2020: report. 2020. Accessed November 24, 2021. https:\/\/www.gov.uk\/government\/statistics\/substance-misuse-treatment-for-adults-statistics-2019-to-2020"},{"key":"bibr51-11782218221111833","first-page":"238","volume":"22","author":"Satre DD.","year":"2015","journal-title":"Clin Psychol"},{"key":"bibr52-11782218221111833","volume":"149","author":"Scholz I","year":"2019","journal-title":"Swiss Med Wkly"},{"key":"bibr53-11782218221111833","doi-asserted-by":"publisher","DOI":"10.1089\/152460900318470"},{"key":"bibr54-11782218221111833","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2012.11.005"},{"key":"bibr55-11782218221111833","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2000.95339310.x"},{"key":"bibr56-11782218221111833","doi-asserted-by":"publisher","DOI":"10.1080\/15504263.2019.1662150"},{"key":"bibr57-11782218221111833","doi-asserted-by":"publisher","DOI":"10.1159\/000438988"},{"key":"bibr58-11782218221111833","unstructured":"Department of Health and Social Care. Drug misuse and dependence: UK guidelines on clinical management. 2017. Accessed November 24, 2021. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/673978\/clinical_guidelines_2017.pdf"},{"key":"bibr59-11782218221111833","unstructured":"Public Health England. New psychoactive substances: a toolkit for substance misuse Commissioners. 2014. Accessed November 24, 2021. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/669429\/nps-a-toolkit-for-substance-misuse-commissioners.pdf"},{"key":"bibr60-11782218221111833","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2015.07.013"},{"key":"bibr61-11782218221111833","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-047283"},{"key":"bibr62-11782218221111833","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"bibr63-11782218221111833","first-page":"790","volume":"74","author":"Page MJ","year":"2021","journal-title":"BMJ"},{"key":"bibr64-11782218221111833","unstructured":"Elsevier. Scopus preview home page. 2021. Accessed November 24, 2021. https:\/\/www.scopus.com\/standard\/marketing.uri"},{"key":"bibr65-11782218221111833","unstructured":"Clarivate Analytics. Web of science service. 2021. Accessed November 24, 2021. https:\/\/wok.mimas.ac.uk\/"},{"key":"bibr66-11782218221111833","unstructured":"National Library of Medicine. Pubmed search home page. 2021. Accessed November 24, 2021. https:\/\/pubmed.ncbi.nlm.nih.gov\/"},{"key":"bibr67-11782218221111833","unstructured":"Wiley. Cochrane Library Advanced Search. 2021. Accessed November 24, 2021. https:\/\/www.cochranelibrary.com\/advanced-search"},{"key":"bibr68-11782218221111833","unstructured":"Wolters KLUWER. Ovid search home page. 2021. Accessed November 24, 2021. https:\/\/ovidsp.ovid.com\/"},{"key":"bibr69-11782218221111833","volume-title":"Systematic Approaches to a Successful Literature Review","author":"Booth A","year":"2016","edition":"2"},{"key":"bibr70-11782218221111833","unstructured":"Hong QN, Pluye P, F\u00e0bregues S, et al. Mixed Methods Appraisal Tool (MMAT) User Guide. 2018. Accessed November 24, 2021. http:\/\/mixedmethodsappraisaltoolpublic.pbworks.com\/w\/file\/fetch\/127916259\/MMAT_2018_criteria-manual_2018-08-01_ENG.pdf"},{"key":"bibr71-11782218221111833","volume":"358","author":"Shea BJ","year":"2017","journal-title":"BMJ"},{"key":"bibr72-11782218221111833","volume":"368","author":"Campbell M","year":"2020","journal-title":"BMJ"},{"key":"bibr73-11782218221111833","unstructured":"Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions Version 6.2. 2021. Accessed November 24, 2021. www.training.cochrane.org\/handbook"},{"key":"bibr74-11782218221111833","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.07.015"},{"key":"bibr75-11782218221111833","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1989.tb00589.x"},{"key":"bibr76-11782218221111833","unstructured":"Ryan R. Heterogeneity and subgroup analyses in Cochrane Consumers and Communication Group reviews: planning the analysis at protocol stage. 2016. Accessed November 24, 2021. https:\/\/cccrg.cochrane.org\/sites\/cccrg.cochrane.org\/files\/public\/uploads\/heterogeneity_subgroup_analyses_revising_december_1st_2016.pdf"},{"key":"bibr77-11782218221111833","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-017-0688-3"},{"key":"bibr78-11782218221111833","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-017-0689-2"},{"key":"bibr79-11782218221111833","volume":"299","author":"Robinson J.","year":"2017","journal-title":"Pharm J"},{"key":"bibr80-11782218221111833","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2004.053"},{"key":"bibr81-11782218221111833","first-page":"306","volume":"306","author":"Burns C.","year":"2021","journal-title":"Pharm J"},{"key":"bibr82-11782218221111833","unstructured":"Department of Health and Social Care. Good for you, good for us, good for everybody A plan to reduce overprescribing to make patient care better and safer, support the NHS, and reduce carbon emissions. 2021. Accessed May 9, 2022. https:\/\/www.gov.uk\/government\/publications\/national-overprescribing-review-report"},{"key":"bibr83-11782218221111833","unstructured":"Pearce C. UK medicines regulator \u2018will consider\u2019 ban on over-the-counter codeine. Pulse. 2020. Accessed May 9, 2022. https:\/\/www.pulsetoday.co.uk\/news\/clinical-areas\/prescribing\/uk-medicines-regulator-will-consider-ban-on-over-the-counter-codeine\/"},{"key":"bibr84-11782218221111833","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103110"}],"container-title":["Substance Abuse: Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11782218221111833","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/11782218221111833","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11782218221111833","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:30:28Z","timestamp":1777692628000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/11782218221111833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":84,"alternative-id":["10.1177\/11782218221111833"],"URL":"https:\/\/doi.org\/10.1177\/11782218221111833","relation":{},"ISSN":["1178-2218","1178-2218"],"issn-type":[{"value":"1178-2218","type":"print"},{"value":"1178-2218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"article-number":"11782218221111833"}}